Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer

Authors: Azeez A. Fatai, Junaid Gamieldien

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Gene expression can be employed for the discovery of prognostic gene or multigene signatures cancer. In this study, we assessed the prognostic value of a 35-gene expression signature selected by pathway and machine learning based methods in adjuvant therapy-linked glioblastoma multiforme (GBM) patients from the Cancer Genome Atlas.

Methods

Genes with high expression variance was subjected to pathway enrichment analysis and those having roles in chemoradioresistance pathways were used in expression-based feature selection. A modified Support Vector Machine Recursive Feature Elimination algorithm was employed to select a subset of these genes that discriminated between rapidly-progressing and slowly-progressing patients.

Results

Survival analysis on TCGA samples not used in feature selection and samples from four GBM subclasses, as well as from an entirely independent study, showed that the 35-gene signature discriminated between the survival groups in all cases (p<0.05) and could accurately predict survival irrespective of the subtype. In a multivariate analysis, the signature predicted progression-free and overall survival independently of other factors considered.

Conclusion

We propose that the performance of the signature makes it an attractive candidate for further studies to assess its utility as a clinical prognostic and predictive biomarker in GBM patients. Additionally, the signature genes may also be useful therapeutic targets to improve both progression-free and overall survival in GBM patients.

Available only for authorised users

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med. 2005; 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331.

Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys. 2012; 84(3):661–7. https://doi.org/10.1016/j.ijrobp.2011.12.086.

Shen D, Liu T, Lin Q, Lu X, Wang Q, Lin F, Mao W. MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study. PLoS ONE. 2014; 9(9):107558. https://doi.org/10.1371/journal.pone.0107558.

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med. 2012; 10(1):250. https://doi.org/10.1186/1479-5876-10-250.

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep. 2010; 23(6):1655–62.PubMed

Yin A-a, Zhang L-h, Cheng J-x, Dong Y, Liu B-l, Han N, Zhang X. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis. PLoS ONE. 2014; 9(1):85102. https://doi.org/10.1371/journal.pone.0085102.

Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. J Clin Oncol. 2008; 26(25):4063–71. https://doi.org/10.1200/JCO.2007.14.4501.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med. 2004; 351(27):2817–26. https://doi.org/10.1056/NEJMoa041588.

Acs G, Kiluk J, Loftus L, Laronga C. Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas. Mod Pathol. 2013; 26(11):1451–60. https://doi.org/10.1038/modpathol.2013.88.

10.

Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MCU, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006; 24(19):3039–47. https://doi.org/10.1200/JCO.2006.05.6564.

11.

van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530–6. https://doi.org/10.1038/415530a.

12.

Soneson C, Gerster S, Delorenzi M. Batch Effect Confounding Leads to Strong Bias in Performance Estimates Obtained by Cross-Validation. PLoS ONE. 2014; 9(6):100335. https://doi.org/10.1371/journal.pone.0100335.

13.

Reese SE, Archer KJ, Therneau TM, Atkinson EJ, Vachon CM, de Andrade M, Kocher J-PA, Eckel-Passow JE. A new statistic for identifying batch effects in high-throughput genomic data that uses guided principal component analysis. Bioinformatics. 2013; 29(22):2877–83. https://doi.org/10.1093/bioinformatics/btt480.

14.

TCGA: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061–8. https://doi.org/10.1038/nature07385.

15.

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabrie S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell. 2010; 17(1):98. https://doi.org/10.1016/j.ccr.2009.12.020.

16.

Kahn AB, Ryan MC, Liu H, Zeeberg BR, Jamison DC, Weinstein JN. SpliceMiner: a high-throughput database implementation of the NCBI Evidence Viewer for microarray splice variant analysis. BMC Bioinformatics. 2007; 8(1):75. https://doi.org/10.1186/1471-2105-8-75.

17.

Liu H, Zeeberg BR, Qu G, Koru AG, Ferrucci A, Kahn A, Ryan MC, Nuhanovic A, Munson PJ, Reinhold WC, Kane DW, Weinstein JN. AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics. 2007; 23(18):2385–90. https://doi.org/10.1093/bioinformatics/btm360.

18.

Iacob G, Dinca E. Current data and strategy in glioblastoma multiforme. J Med Life. 2009; 2(4):386–93.PubMedPubMedCentral

19.

Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007; 25(29):4562–8. https://doi.org/10.1200/JCO.2006.08.1935.

20.

Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung W, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L. The Somatic Genomic Landscape of Glioblastoma. Cell. 2013; 155(2):462–77. https://doi.org/10.1016/j.cell.2013.09.034.

21.

Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R, Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014; 5(6):1392–433. https://doi.org/10.18632/oncotarget.1891.

22.

Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I. Chemotherapy and signaling: How can targeted therpies supercharge cytotoxic agents?Cancer Biol Ther. 2010; 10(9):839–53. https://doi.org/10.4161/cbt.10.9.13738.

23.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther. 2008; 7(10):3141–9. https://doi.org/10.1158/1535-7163.MCT-08-0642.

24.

Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst. 2001; 93(19):1434–6. https://doi.org/10.1093/jnci/93.19.1434.

25.

Sherman-Baust CA, Becker KG, Wood III WH, Zhang Y, Morin PJ. Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res. 2011; 4:21. https://doi.org/10.1186/1757-2215-4-21.

26.

Long J, Zhang Y, Yu X, Yang J, LeBrun D, Chen C, Yao Q, Li M. Overcoming Drug Resistance in Pancreatic Cancer. Expert Opin Ther Targets. 2011; 15(7):817–28. https://doi.org/10.1517/14728222.2011.566216.

27.

Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resist Updat. 2012; 15(5):249–57. https://doi.org/10.1016/j.drup.2012.10.003.

28.

Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011; 103(16):1222–6. https://doi.org/10.1093/jnci/djr246.

29.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked?Free Radic Biol Med. 2010; 49(11):1603–16. https://doi.org/10.1016/j.freeradbiomed.2010.09.006.

30.

West KA, Castillo SS, Dennis PA. Activation of the PI3k/Akt pathway and chemotherapeutic resistance. Drug Resist Updat Rev Commentaries Antimicrob Anticancer Chemother. 2002; 5(6):234–48.

31.

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug Resistance in Cancer: An Overview. Cancers. 2014; 6(3):1769–92. https://doi.org/10.3390/cancers6031769.

32.

Davis AP, Murphy CG, Johnson R, Lay JM, Lennon-Hopkins K, Saraceni-Richards C, Sciaky D, King BL, Rosenstein MC, Wiegers TC, Mattingly CJ. The Comparative Toxicogenomics Database: update 2013. Nucleic Acids Res. 2013; 41(Database issue):1104–14. https://doi.org/10.1093/nar/gks994.

33.

Guyon I, Weston J, Barnhill S, Vapnik V. Gene Selection for Cancer Classification using Support Vector Machines. Mach Learn. 2002; 46(1-3):389–422. https://doi.org/10.1023/A:1012487302797.

34.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MCM, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26(18):3015–24. https://doi.org/10.1200/JCO.2007.15.7164.

35.

Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2017; 45:362–8. https://doi.org/10.1093/nar/gkw937.

36.

Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC. Combining gene signatures improves prediction of breast cancer survival. PLoS ONE. 2011; 6(3):17845. https://doi.org/10.1371/journal.pone.0017845.

37.

Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, Penn LZ, Shepherd FA, Jurisica I, Der SD, Tsao MS. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25(35):5562–9. https://doi.org/10.1200/JCO.2007.12.0352.

38.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987–96. https://doi.org/10.1056/NEJMoa043330.

39.

Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance. Drug Resist Updat Rev Commentaries Antimicrob Anticancer Chemother. 2008; 11(3):63–76. https://doi.org/10.1016/j.drup.2008.03.001.

40.

Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA, Neves JH, Machado-Santelli GM. The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res CR. 2014; 33(1):37. https://doi.org/10.1186/1756-9966-33-37.

41.

Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer Targets Ther. 2014; 6:1–13. https://doi.org/10.2147/BCTT.S37638.

42.

Shi RY, Yang XR, Shen QJ, Yang LX, Xu Y, Qiu SJ, Sun YF, Zhang X, Wang Z, Zhu K, Qin WX, Tang ZY, Fan J, Zhou J. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer. 2013; 119(5):993–1003. https://doi.org/10.1002/cncr.27788.

43.

Wong SCC, He CW, Chan CML, Chan AKC, Wong HT, Cheung MT, Luk LLY, Au TCC, Chiu MK, Ma BBY, Chan ATC. Clinical Significance of Frizzled Homolog 3 Protein in Colorectal Cancer Patients. PLoS ONE. 2013; 8(11):79481. https://doi.org/10.1371/journal.pone.0079481.

44.

Zheng L, Sun D, Fan W, Zhang Z, Li Q, Jiang T. Diagnostic Value of SFRP1 as a Favorable Predictive and Prognostic Biomarker in Patients with Prostate Cancer. PLoS ONE. 2015; 10(2):0118276. https://doi.org/10.1371/journal.pone.0118276.

45.

Saran U, Arfuso F, Zeps N, Dharmarajan A. Secreted frizzled-related protein 4 expression is positively associated with responsiveness to Cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell Biol. 2012; 13(1):25. https://doi.org/10.1186/1471-2121-13-25.

46.

Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P, Thompson AM. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer. J Int Du Cancer. 2010; 127(2):355–60. https://doi.org/10.1002/ijc.25034.

47.

Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod Pathol. 2014; 27(1):87–95. https://doi.org/10.1038/modpathol.2013.125.

48.

Allera-Moreau C, Rouquette I, Lepage B, Oumouhou N, Walschaerts M, Leconte E, Schilling V, Gordien K, Brouchet L, Delisle MB, Mazieres J, Hoffmann JS, Pasero P, Cazaux C. DNA replication stress response involving PLK1, CDC6, POLQ. RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. Oncogenesis. 2012; 1(10):30. https://doi.org/10.1038/oncsis.2012.29.

49.

Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J, Chen M. The prognostic value of CDKN2a hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer. 2013; 108(12):2542–8. https://doi.org/10.1038/bjc.2013.251.

50.

Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep. 2003; 10(4):935–8. https://doi.org/10.3892/or.10.4.935.

51.

Mihara M, Shintani S, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T, Wong DT. Overexpression of CDK2 is a prognostic indicator of oral cancer progression. Jpn J Cancer Res Gann. 2001; 92(3):352–60.CrossRefPubMed

52.

Cretu A, Sha X, Tront J, Hoffman B, Liebermann DA. Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther. 2009; 7(A):268–76.PubMedPubMedCentral

53.

Zerbini LF, Libermann TA. GADD45 Deregulation in Cancer: Frequently Methylated Tumor Suppressors and Potential Therapeutic Targets. Clin Cancer Res. 2005; 11(18):6409–13. https://doi.org/10.1158/1078-0432.CCR-05-1475.

54.

Guo W, Dong Z, Guo Y, Chen Z, Kuang G, Yang Z. Methylation-mediated repression of GADD45a and GADD45g expression in gastric cardia adenocarcinoma. Int J Cancer J Int Du Cancer. 2013; 133(9):2043–53. https://doi.org/10.1002/ijc.28223.

55.

Guo W, Zhu T, Dong Z, Cui L, Zhang M, Kuang G. Decreased expression and aberrant methylation of Gadd45g is associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Clin Exp Metastasis. 2013; 30(8):977–92. https://doi.org/10.1007/s10585-013-9597-2.

56.

Zhang K, Wang X-q, Zhou B, Zhang L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Familial Cancer. 2013; 12(3):449–58. https://doi.org/10.1007/s10689-013-9607-1.

57.

Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GHJ, Elinzano H, Chao ST. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro-Oncol. 2011; 13(4):428–36. http://dx.doi.org/10.1093/neuonc/nor005.

58.

Thumma SR, Fairbanks RK, Lamoreaux WT, Mackay AR, Demakas JJ, Cooke BS, Elaimy AL, Hanson PW, Lee CM. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012; 10:75. https://doi.org/10.1186/1477-7819-10-75.

59.

Bozdag S, Li A, Riddick G, Kotliarov Y, Baysan M, Iwamoto FM, Cam MC, Kotliarova S, Fine HA. Age-Specific Signatures of Glioblastoma at the Genomic. Genetic, and Epigenetic Levels. PLoS ONE. 2013; 8(4):62982. https://doi.org/10.1371/journal.pone.0062982.

60.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Nowsheen S. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015; 35:25–54. https://doi.org/10.1016/j.semcancer.2015.02.006.

61.

Zhang J, Chen YH, Lu Q. Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy. Futur Oncol. 2010; 6(4):587–603. https://doi.org/10.2217/fon.10.15.

62.

Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012; 30(7):679–92. https://doi.org/10.1038/nbt.2284.

63.

Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, Aittokallio T. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol. 2013; 9(9):1003226. https://doi.org/10.1371/journal.pcbi.1003226.

64.

Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online mendelian inheritance in man (OMIM®;), an online catalog of human genes and genetic disorders. 2015; 43:789–98. https://doi.org/10.1093/nar/gku1205.

Title: A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer
Authors: Azeez A. Fatai
Junaid Gamieldien
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4103-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Determinants of cancer screening awareness and participation among Indonesian women

Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study

Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes

Punch biopsies shorten time to clearance of high-risk human papillomavirus infections of the uterine cervix

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer